- Home
- KLTO vs PPBT Comparison
KLTO vs PPBT Comparison
Compare KLTO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- PPBT
- Stock Information
- Founded
- KLTO 2019
- PPBT 2010
- Country
- KLTO United States
- PPBT Israel
- Employees
- KLTO N/A
- PPBT N/A
- Industry
- KLTO
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- PPBT Health Care
- Exchange
- KLTO NYSE
- PPBT Nasdaq
- Market Cap
- KLTO 5.9M
- PPBT 6.2M
- IPO Year
- KLTO N/A
- PPBT N/A
- Fundamental
- Price
- KLTO $1.34
- PPBT $2.40
- Analyst Decision
- KLTO
- PPBT Strong Buy
- Analyst Count
- KLTO 0
- PPBT 1
- Target Price
- KLTO N/A
- PPBT $33.00
- AVG Volume (30 Days)
- KLTO 22.5M
- PPBT 20.0K
- Earning Date
- KLTO 08-15-2025
- PPBT 08-15-2025
- Dividend Yield
- KLTO N/A
- PPBT N/A
- EPS Growth
- KLTO N/A
- PPBT N/A
- EPS
- KLTO N/A
- PPBT N/A
- Revenue
- KLTO N/A
- PPBT N/A
- Revenue This Year
- KLTO N/A
- PPBT N/A
- Revenue Next Year
- KLTO N/A
- PPBT N/A
- P/E Ratio
- KLTO N/A
- PPBT N/A
- Revenue Growth
- KLTO N/A
- PPBT N/A
- 52 Week Low
- KLTO $0.11
- PPBT $2.00
- 52 Week High
- KLTO $3.91
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- PPBT 47.27
- Support Level
- KLTO N/A
- PPBT $2.35
- Resistance Level
- KLTO N/A
- PPBT $2.58
- Average True Range (ATR)
- KLTO 0.00
- PPBT 0.12
- MACD
- KLTO 0.00
- PPBT 0.01
- Stochastic Oscillator
- KLTO 0.00
- PPBT 43.75
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.